Curbing the costly trend: Exploring the need for a progressive approach to the management of specialty pharmaceuticals under the medical benefit

American Health and Drug Benefits

Volumn 5, Issue 5, 2012, Pages

  Jacobs, Michael S ^a   Johnson, Kjel A ^b  

^a Truveris Inc   (United States)

^b Strategy and Business Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL PRODUCT; IMMUNOGLOBULIN; PRESCRIPTION DRUG; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TRASTUZUMAB;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG FORMULARY; DRUG INDUSTRY; DRUG MARKETING; DRUG PROGRAM; DRUG QUALITY; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEALTH INSURANCE; MEDICATION THERAPY MANAGEMENT; REIMBURSEMENT; TREND STUDY;

EID: 84865482834     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Medco 2011 Drug Trend Report. Healthcare 2020: fast forward to the future. Med Benefits. 2011;28:1-2.
2. Express Scripts. 2010 Drug Trend Report. April 2011. www.express-scripts.com/research/research/dtr/archive/2010/dtrFinal.pdf. Accessed July 31, 2012.
3. ICORE Healthcare. Medical Pharmacy & Oncology Trend Report. 2nd ed. 2011. www.icorehealthcare.com/media/439145/icore_trend%20report_2011.pdf. Accessed July 31, 2012.
4. US Food and Drug Administration. Guidance for industry on biosimilars: Q & As regarding implementation of the BPCI Act of 2009. February 2012. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm259797.htm. Accessed July 31, 2012.
5. Howell P. How much cheaper will biosimilars be? March 2, 2012. www.fiercepharma.com/story/how-much-cheaper-will-biosimilars-be/2012-03-02. Accessed July 31, 2012.
6. Community Oncology Alliance. Community Oncology Cancer Care Practice Impact Report. March 31, 2011. http://communityoncology.org/UserFiles/files/87f3205e-ee73-4b03-85fb-094870cc430d/COA%20Community%20Oncology%20Practice%20Impact%20Report%203-31-11(1).pdf. Accessed July 31, 2012.
7. National Comprehensive Cancer Network. NCCN guidelines for the treatment of cancer by site. www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed August 2, 2012.
8. New control techniques on the horizon for payer oncology management [press release]. Millburn, NJ: The Zitter Group; April 6, 2012. www.zitter.com/download/New%20Control%20Techniques%20on%20the%20Horizon%20for%20Payer%20Oncology%20Management.pdf. Accessed July 31, 2012.
9. Neubauer MA, Hoverman JR, Kolodziej M, et al. Cost effectiveness of evidencebased treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract. 2010;6:12-18.
10. Magellan's Medical Pharmacy Solutions product manages specialty drug costs against rising trends [press release]. Avon, CT: Magellan Health Services; May 16, 2011. http://ir.magellanhealth.com/releasedetail.cfm?ReleaseID=577917. Accessed July 31, 2012.